Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00047710
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Accepted

Interventions

  • Bevacizumab — DRUG
    Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).
  • Capecitabine — DRUG
    650mg/m\^2 taken by mouth twice a day 15-52 during the radiotherapy.
  • Radiotherapy — RADIATION
    Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.

Study Details

The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer. The effect that this combination treatment has on the tumor will also be studied.

Key Dates

First listed
Oct 16, 2002
Start date
Sep 30, 2002
Status verified
Jul 2012
Primary completion
Jul 31, 2006
Completion
Jul 31, 2006

Study Design

Enrollment
48 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab
    Radiation, Bevacizumab, and Capecitabine

Primary Outcome Measure

Safety of combination Radiation, Bevacizumab, and Capecitabine. [ Time Frame: 6 weeks after the completion of therapy ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MDAnderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
University of Texas MDAnderson Cancer Center· Houston, TX

Related Studies